Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
OCOG-ALMERA trial: what clinicians have said so far
Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy
- NCT02115464 ↗
- Terminated
- Ontario Clinical Oncology Group (OCOG)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on OCOG-ALMERA (metformin in locally advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OCOG-ALMERA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Lung Cancer
- Interventions
- Metformin plus Chemo-radiotherapy; Chemo-radiotherapy
- Arms
- Metformin plus Chemo-radiotherapy · Experimental
- Chemo-radiotherapy · Active comparator
- Enrollment
- 54
- Primary outcomes
- Progression free survival
- Sponsor
- Ontario Clinical Oncology Group (OCOG) with Canadian Institutes of Health Research (CIHR)
- Start
- Dec 17, 2014
- Primary completion
- Mar 9, 2020
- Results posted
- No
- Registry record
- NCT02115464 · updated Apr 22, 2020
Publications
linked from the registry- Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmed N, Abdulkarim B, Roa W, Robinson A, Swaminath A, Okawara G, Wierzbicki M, Valdes M, Levine M. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021 Sep 1;7(9):1333-1341. doi: 10.1001/jamaoncol.2021.2328. PubMed 34323924